AFT Pharmaceuticals Limited (NZX: AFT) Opening European office, signs New Partners for MXG

Wednesday 18th November 2020

AFT Pharmaceuticals (NZX: AFT , ASX: AFP) announces the establishment of a new subsidiary in Ireland, to drive the growth of the company’s products in Europe. It also announces new licensing, distribution and supply agreements for:

• Maxigesic IV® in Ireland, and Thailand

• Maxigesic tablets in Greece, Pakistan and Ecuador

AFT Managing Director Dr Hartley Atkinson said the decision to open a European representative office is a response to the ongoing growth in demand in the region for its Maxigesic product range.

“Maxigesic IV® has now been submitted for registration in 27 European countries and 17 of these have been approved. As the number of registrations increases, so too will the need for AFT to provide local support to Licensees and Distributors such as regulatory services. Eddie is well placed to oversee this support and ensure AFT makes the most of the significant opportunities we see in the region.”

According to an independent report by DelveInsight* published earlier this year, Maxigesic in its various dose forms has the potential to generate sales of more than $80 million across Europe’s major markets and the UK by 2028.

“We are also delighted to have secured agreements for Maxigesic IV® distribution with Ireland’s Jed Pharmaceuticals for Ireland, along with Alliance Pharma in Thailand. We have concluded licensing agreements with Switzerland’s Acino for Maxigesic oral dose forms in Ecuador and Greek’s market leading Elpen Pharmaceuticals, along with distribution agreements with the Karachi-based Excel Healthcare Laboratories for Pakistan,” Dr Atkinson said.

See the links below for more details:

AFT opening European office, signs new partners for Maxigesic IV and Oral range

Source: AFT Pharmaceuticals Limited

Comments from our readers

No comments yet